Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.41 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.36 |
| ▸ | CES2 | O00748 | 1/20 | 0.36 |
| ▸ | CES1 | P23141 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methylcyclopentane SCHEMBL27727030 | 0.87 | FFAR3 (0.53) | CYP1A2EPHX1ALDH1A1FFAR3CES2 | |
| Propionic Acid SCHEMBL4088363 | 0.87 | FFAR3 (0.53) | CYP1A2EPHX1ALDH1A1FFAR3CES2 | |
| Propionic Acid SCHEMBL8614869 | 0.87 | FFAR3 (0.53) | CYP1A2EPHX1ALDH1A1FFAR3CES2 | |
| Bicarbonate SCHEMBL4695324 | 0.84 | EPHX1 (0.50) | CYP1A2EPHX1ALDH1A1CES2CES1 | |
| Bicarbonate SCHEMBL17847302 | 0.84 | EPHX1 (0.50) | CYP1A2EPHX1ALDH1A1CES2CES1 | |
| Bicarbonate SCHEMBL8913592 | 0.84 | EPHX1 (0.50) | CYP1A2EPHX1ALDH1A1CES2CES1 | |
| Chloroacetic Acid SCHEMBL1783141 | 0.83 | TSHR (0.48) | CYP1A2EPHX1ALDH1A1FFAR3CES2 | |
| Acetic Acid SCHEMBL4087167 | 0.81 | EPHX1 (0.48) | CYP1A2EPHX1ALDH1A1FFAR3CES2 | |
| Acetic Acid SCHEMBL938460 | 0.81 | EPHX1 (0.48) | CYP1A2EPHX1ALDH1A1FFAR3CES2 | |
| Acetic Acid SCHEMBL4093239 | 0.81 | EPHX1 (0.48) | CYP1A2EPHX1ALDH1A1FFAR3CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8653301-B2 | Tricyclodecane monomethanol monocarboxylic acid and derivatives thereof | HITACHI CHEMICAL COMPANY, LTD. (JP) | 2014-02-18 | — | — | US | disclosed |
| EP-2492258-A1 | METHOD FOR MANUFACTURING A TRICYCLODECANE MONO-METHANOL MONOCARBOXYLIC ACID DERIVATIVE | Hitachi Chemical Company, Ltd. (JP) | 2012-08-29 | — | — | EP | disclosed |
| US-20120203026-A1 | METHOD FOR MANUFACTURING TRICYCLODECANE MONO-METHANOL MONOCARBOXYLIC ACID DERIVATIVE | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 2012-08-09 | — | — | US | disclosed |
| EP-2474519-A1 | TRICYCLODECANE MONOMETHANOL MONOCARBOXYLIC ACID AND DERIVATIVES THEREOF | Hitachi Chemical Company, Ltd. (JP) | 2012-07-11 | — | — | EP | disclosed |
| US-20120157705-A1 | TRICYCLODECANE MONOMETHANOL MONOCARBOXYLIC ACID AND DERIVATIVES THEREOF | HITACHI CHEMICAL COMPANY, LTD. (JP) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120203026-A1 | METHOD FOR MANUFACTURING TRICYCLODECANE MONO-METHANOL MONOCARBOXYLIC ACID DERIVATIVE | MCCC2, HACL2, HPD | CYP1A2 348/4885EPHX1 4631/4885ALDH1A1 356/4885 |
| US-20120157705-A1 | TRICYCLODECANE MONOMETHANOL MONOCARBOXYLIC ACID AND DERIVATIVES THEREOF | MCCC2, HADHA, MLYCD | CYP1A2 460/4885EPHX1 4197/4885ALDH1A1 592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.